Patient Advocates Argue Exercising Bayh-Dole " March-In " Rights Reasonable to Ensure Ongoing Supply of an Insulin Novo Nordisk Intends to Discontinue

Back in 2016 (when President Obama was still in office), the trade group known as the Pharmaceutical Research and Manufacturers of America (better known by the acronym PhRMA) claimed in an organization-published white paper (seehttps://web.archive.org/web/20161022175500/https://phrma.org/sites/default/files/pdf/bayh-dole-act-white-paper-summary.pdf for an archived copy of that paper from PhRMA; note that it has since been removed from PhRMA ' s website, hence I found a copy on the Internet Archive) that championed the Bayh-Dole Act of 1980. Understand that what PhRMA really wants to prevent a particular provision of the Bayh-Dole Act from ever operating in order to address prescription drug prices. That provision is known as " march-in " rights. To do this, the PhRMA trade organization made a variety of baseless assertions about Bayh-Dole that could not be supported with any data or involved data that had absolutelynothing to do with Bayh-Dole. In fact, its entire opposition to Bayh-Dole " march-in " provisions is having the government use those provisions over drug prices. But what about reasons other than price? PhRMA would prefer to not acknowledge the possibility of such a thing happening. But the industry has discontinued products before, and that is currently happening in the insulin space. Specifically, refer tomy recent blog post about the November 8, 2023 announcement from Novo Nordisk so it could instead redeploy internal manufacturing capac...
Source: Scott's Web Log - Category: Endocrinology Tags: march-in rights 2024 Alliance to Protect Insulin Choice APIC Bayh-Dole insulin detemir Levemir Novo Nordisk Source Type: blogs